Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
2.
Oral Maxillofac Surg ; 28(2): 809-818, 2024 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-38261079

RESUMO

PURPOSE: To evaluate the clinical and aesthetic outcome of percutaneous injection of sclerosant agents to treat head and neck cystic malformations (HNCM) and to assess their recurrence rate based on histology and site. METHODS: Fifty-four subjects (mean age 46 years) with HNCM treated by percutaneous injection of sclerosant agents between January and December 2017 were included. Imaging and clinical data before and after the procedure were collected. Quality of Life Index, Pain Visual Analogue Scale, and Aesthetic Scale scores were measured to assess clinical and aesthetic outcomes. A size reduction of ≥ 70% assessed through the visual scale was considered significant. RESULTS: Of the 54 HNCM, there were 26 (48%) lymphatic malformations (LM), 13 (24%) salivary epithelial duct cysts of the parotid gland, 12 (22%) salivary mucoceles, and 3 (5%) branchial cysts. A significant size reduction and a satisfactory clinical-aesthetic outcome were observed in all types of LM. The number of reinterventions was significantly associated with the number of lesions (p < 0.001). The lowest number of interventions was observed in macrocystic lymphatic malformations (average of 1.2 interventions). All salivary epithelial duct cysts showed a significant reduction in size, a satisfactory clinical-aesthetic outcome, and an average of 1.16 interventions per patient. Mucoceles had a worse response, with only 3/14 patients showing a satisfactory and long-lasting clinical outcome (average of 1.16 interventions). Treatment of branchial cysts showed the worst outcome with a limited clinical response (3/3). CONCLUSION: Percutaneous injection of sclerosant agents may be considered as a first-line treatment for LM and salivary epithelial duct cysts.


Assuntos
Cistos , Anormalidades Linfáticas , Soluções Esclerosantes , Humanos , Soluções Esclerosantes/uso terapêutico , Soluções Esclerosantes/administração & dosagem , Feminino , Masculino , Pessoa de Meia-Idade , Adulto , Adolescente , Cistos/tratamento farmacológico , Anormalidades Linfáticas/tratamento farmacológico , Anormalidades Linfáticas/terapia , Criança , Idoso , Adulto Jovem , Resultado do Tratamento , Pré-Escolar , Escleroterapia/métodos , Mucocele/tratamento farmacológico , Branquioma/tratamento farmacológico , Estética
6.
Melanoma Res ; 32(1): 63-66, 2022 02 01.
Artigo em Inglês | MEDLINE | ID: mdl-34725315

RESUMO

Eruptive melanocytic nevi (EMN) describes the sudden onset of cutaneous nevi over weeks or months. Such a clinical event is generally seen in young adult patients and may be related to several possible causes. We report here a case of EMN in an old male patient followed up for a thick amelanotic cutaneous melanoma. A few months after the eruption, multiple hepatic masses, diagnosed as melanoma metastasis, were detected. The presented case may suggest that EMN may be a paraneoplastic phenomenon of alert in patients being followed for melanoma or other malignancies.


Assuntos
Melanoma Amelanótico/complicações , Nevo Pigmentado/etiologia , Idoso de 80 Anos ou mais , Humanos , Masculino , Nevo Pigmentado/fisiopatologia , Síndromes Paraneoplásicas
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA